Replies to post #190681 on Biotech Values

[DewDiligence]

Re: OCRX

Your assessment is unduly bearish, IMO. For instance, OCRX might ink a partnership deal for OCR-002 that defers a financing transaction until 2016 or obviates the need for it entirely.

Further, on today’s CC, OCRX stated that their internal models predict STOP-HE (after patient upsizing) will show a 1.5-2-day improvement relative to SoC in the primary endpoint, which is more bullish than my own prior assessment of an improvement of about 1 day (#msg-112399186, bottom).

The enterprise value is now <$20M.

I bought more shares today @$3.31.